semaglutide cardiovascular risk 🔴Cardiovascular outcomes with by severity of chronic kidney disease in type 2 diabetes: the FLOW trial⤵️ 🔹Semaglutide significantly reduced the of CV death/MI/stroke regardless of baseline CKD severity in participants Wegovy lowers cardiovascular risk for
Description
Some patients describe it as a taste of metal in mouth and nausea, especially in the early stages or during dose increases
doi: 10.1177/2042018821989238
Two approaches were used to assess a potential association between semaglutide and NAION: (1) an active-comparator cohort design (assessing outcomes of the new semaglutide users to the other drugs) and (2) a self-controlled case series (comparing risk during exposure vs
Front Microbiol 13:1109651 Pati B, Sendh S, Sahu B, Pani S, Jena N, Bal NC (2023) Recent advancements in pharmacological strategies to modulate energy balance for combating obesity
